

Embololic Protection Devices

January 2007



Greystone

associates

Greystone Associates

98 Route 101A • Suite 17

Amherst, NH 03031

603-595-4340 • fax 603-804-0466

For patients suffering from CAH, PAD and other forms of vascular insufficiency, the evolving capabilities of embolic protection devices (EPD) have become an essential element in physician decisions and treatment outcomes.

While the evolutionary success of embolic protection device has been impressive, several issues must be addressed in order for the technology to fully expand beyond SVG and PCI procedures.

The embolic protection sector has been marked by a high level of technology acquisition activity, as established players seek to protect their existing franchise and expand product offerings.

Promising indications for embolic protection include atrial fibrillation-related embolism protection and interventional procedures for cerebrovascular defects.

Greystone Associates is pleased to announce the publication of a new market study. **Embollic Protection Devices** is a comprehensive evaluation and analysis of the devices and companies shaping this dynamic segment of the interventional cardiology sector.

Published in January (2007), the study is designed to provide cardiovascular company decision makers, device designers and developers, healthcare technologists and market sector stakeholders with a detailed understanding of the commercial embolic protection products, development stage devices and technology initiatives defining the practice of embolic protection in cardiovascular medicine. Provider organization business managers, healthcare administrators and investors will also benefit from this publication.

Evolutionary Device Improvements Creating Opportunities

Patient morbidity due to conditions where blood flow to tissues is impaired or otherwise compromised is one of the most significant healthcare segments worldwide, affecting as many as twenty-five million in the U.S. alone. For the millions of patients of cardiovascular disease, peripheral artery disease, and related vascular insufficiency conditions, interventional cardiology is the primary therapeutic avenue for alleviating symptoms and improving Quality of Life. The number of interventional procedures performed in developed countries has steadily increased over the past 10 years and will continue to grow at a healthy rate. For these patients, the evolving capabilities of embolic protection devices (EPD) have become an essential element in physician decisions and treatment outcomes.

While the evolutionary success of embolic protection device has been impressive, several issues must be addressed in order for the technology to fully expand beyond SVG and PCI procedures. Promising indications for embolic protection include atrial fibrillation-related embolism protection and interventional procedures for cerebrovascular defects.

This sector has been marked by a high level of technology acquisition activity, as established players seek to protect their existing franchise and expand product offerings. Several companies are developing novel approaches to EPD that offer several advantages. These technologies, while in early clinical trial stages, have the potential to influence the direction of future programs and alliance activity.

Executive Summary

Interventional Cardiology Market Dynamics

- Cardiovascular Health Demographics
- Established Therapeutic Targets
- Patient Perceptions and Expectations
- Factors Limiting Growth
- Competitive Landscape

Embolic Protection Market Drivers

- Saphenous Vein Grafts
- Percutaneous Coronary Intervention (PCI)
 - PTCA
 - Stenting Procedures
 - Stent Placement
 - Coronary Artery Stenting
 - Carotid Artery Stenting
 - Stent Retrieval
- Atrial Fibrillation
- Cerebrovascular Defects

Embolic Protection Technology and Design Factors

- Occlusion Devices
 - Proximal Occlusion
 - Distal Occlusion
- Filter-based Devices
- Occlusive Gels

Commercial Embolic Protection Devices

- Angioguard (Cordis)
- Embol-X Glide (Edwards Lifesciences)
- Emboshield PRO (Abbott Vascular)
- FAST Funnel Catheter (Genesis Medical)
- FilterWire EZ (Boston Scientific)
- Guardwire Plus (Medtronic)
- Interceptor Plus (Medtronic)
- MO.MA (Invatec)
- Proxis (St. Jude Medical)
- Rubicon Filter (Boston Scientific)
- Rx Accunet (Abbott Vascular)
- SpideRx (ev3)
- Triactiv (Kensey Nash)

Development-stage Embolic Protection Devices

- AEPD (Sagax/MIVT)
- Fibernet (Lumen Biomedical)
- Gore Embolic Liquid (WL Gore)
- Watchman (Atritech)

Market Factors

- FDA Guidance and Regulatory Climate
- Clinical Trial Factors
- Patent Life/Life Cycle Issues
- Design Partnerships

Company Profiles

- Detailed Profiles of 14 Market Participants

Market Data

The study presents qualitative and quantitative data and information on key market measures and benchmarks:

- Embolic Protection Device Segment Analysis
- EPD Market Drivers
- Commercial Device Assessments
- Development-stage Device Evaluations
- EPD Design Factors
- Competitive Landscape
- Detailed Participant Profiles
- Alliance Activity
- Market Dynamics and Sensitivities
- Proprietary Technology
- Economic Factors
- Technology Risk Factors
- Regulatory Risk Factors

Forecasts and projections cover the period from 2007 to 2010.

Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, supply chain participants, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

Feature Summary

- Analyzes commercial embolic protection devices and assesses the market potential for existing and probable future devices
- Examines embolic protection device design issues and evolving technology and factors
- Provides detailed status of embolic protection devices currently in development
- Forecasts the impact of embolic protection devices on interventional cardiology markets
- Profiles embolic protection device companies, their technologies, acquisition and alliance activity, and business strategies
- Evaluates the impact of economic, technology, and regulatory factors on embolic protection devices

Report Format and Availability

This report is available in hard copy or electronic format. A site license for a single physical location and a global license are also available. Publication is scheduled for the second half of January, with availability on or before January 25th.

About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on medical market strategies, product commercialization, venture development, and market research. We assist medical market participants in achieving their business objectives through the creation of detailed business development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge necessary to refine and execute their marketing plans and achieve their financial targets.

Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address. Orders which are not prepaid must indicate the billing address. There is no charge for handling and shipping for destination addresses within the continental US.

Payment

We accept the following forms of payment:

Company Check: Please make checks payable to 'Greystone Associates'

Credit Cards: We accept MasterCard, Visa and American Express

Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer. There is a \$50 per copy shipping and handling charge for international shipments.

Wire Transfers: Bank of New Hampshire
300 Franklin Street
Manchester, NH 03103
(Call for Account Information)

Mailing Address: P.O. Box 1362
Amherst, NH 03031

Emblonic Protection Devices

Format	Price (U.S. funds)	Quantity	Total
Electronic	\$975.00		
Site License	\$1,850.00		
Global License	\$3,500.00		
Total Payment (U.S. funds)			

Method of Payment: Company Check    Wire Transfer (International)

Card Number: _____ Name on Card _____

Expiration Date: _____ Signature _____

Company: _____ Phone: _____

Name: _____ Fax: _____

Title: _____ E-Mail: _____

Shipping Address: _____

Signature: _____